Fibrinolytic Disorders

Abnormalities in the fibrinolytic system may be associated with thrombosis or bleeding. Acquired clotting or bleeding abnormalities should be considered before the less common congenital fibrinolytic abnormalities.

Tabs Content

Clinical Overview

Diagnosis

Indications for Testing

High clinical suspicion for a fibrinolytic disorder after exclusion of common disorders of coagulation
- Uncommon factor deficiencies should also be considered

Laboratory Testing

Plasminogen activator inhibitor-1 (PAI-1)
- Diurnal variation – higher values in the morning, lower values in the afternoon
- Identification of PAI-1 deficiency is complex – values should be interpreted in conjunction with tissue plasminogen activator (tPA) values
  - Many laboratory assays are designed to identify elevated PAI-1 levels and cannot accurately quantify low values
  - Levels below the limit of quantification may be seen in both PAI-1-deficient patients and in individuals with normal levels
  - Specialized testing may be necessary to definitively diagnose severe PAI-1 deficiency
Plasminogen – activity testing
Alpha-2-antiplasmin – activity testing
tPA – antigen testing
Genotyping (SERPINE1)
- Consider in patient with recurrent deep vein thrombosis and negative workup for common defects

Differential Diagnosis

Factor deficiency
- Factor VIII or IX deficiency most common
- von Willebrand disease
Functional platelet disorder

Background

Pathophysiology

Formation of a fibrin clot occurs in response to vascular injury
Fibrinolytic system breaks down fibrin clot, converting fibrin to soluble degradation products
- Components of the fibrinolytic system include plasminogen, plasminogen activators, plasminogen activator inhibitors, and alpha-2-antiplasmin
- Fibrinolysis is precisely regulated by these activators, inhibitors, and cofactors

Components of Fibrinolytic System

Plasminogen

Pathophysiology
- Synthesized in the liver and converted to its active form (plasmin) by plasminogen activators
- Plasmin degrades fibrin (and fibrinogen), forming soluble fibrin degradation products
- Excessive plasmin formation may result in increased fibrinolysis and bleeding
Deficiency
- Inherited
  - Incidence – <1/million (rare)
  - Inheritance – autosomal recessive
  - Clinical presentation – ligneous conjunctivitis; similar ligneous lesions in gingiva, ear, respiratory tract, and female genitourinary tract; altered wound healing; pseudomembrane function
- Acquired
  - May be due to liver disease or disseminated intravascular coagulation
Thrombotic risk
- Heterozygotes – no apparent increase in risk of thrombosis
- Homozygotes – risk of thrombosis remains unclear

tPA

Pathophysiology
- Plasminogen activator is synthesized by endothelial cells and released in response to endothelial cell stimulation
- tPA converts plasminogen to plasmin, which subsequently degrades fibrin (and fibrinogen), forming soluble fibrin degradation products
  - Low concentrations of circulating tPA are found in the blood
Clinical presentation
- Increased tPA results in increased fibrinolysis and bleeding
- Acquired abnormalities
  - tPA is an acute phase reactant and may be elevated in patients with sepsis, cancer, surgery, pregnancy, or metabolic syndrome
Thrombotic risk
- Deficiency may raise risk for thrombosis, but association is uncertain

PAI-1

Pathophysiology
- Released primarily by the liver and adipose tissue
- Levels are regulated by metabolic factors such as triglycerides, cholesterol, and insulin
- Binds to and inhibits plasminogen activators such as tPA, forming inactive complexes that are cleared by the liver
  - PAI-1 is found in its active form in blood, as well as in an inactive form (primarily in platelets), and in complexes with plasminogen activators
  - Acquired abnormalities
    - PAI-1 is an acute phase reactant and may be elevated in patients with metabolic syndrome, cancer, surgery, pregnancy, or inflammation such as sepsis
  - Most PAI-1 assays are designed to detect increased PAI-1 concentration rather than PAI-1 deficiency; low concentrations may not be accurately quantified
Bleeding potential
- Inherited deficiency (congenital PAI-1 deficiency)
  - Incidence – rare (in U.S., most common in the Old Order Amish community)
  - Inheritance – autosomal recessive
- Clinical presentation
  - Heterozygotes usually do not present with bleeding disorders
  - Homozygotes may present with moderate to severe bleeding
    - Bleeding is usually posttraumatic rather than spontaneous
Thrombotic risk
- Elevated levels of PAI-1 may be associated with venous or arterial thrombosis, although routine testing of patients with thrombophilia for this disorder is not recommended
- Inherited polymorphism – single guanosine nucleotide deletion/insertion polymorphism (4G/5G) at -675 bp of the SERPINE1 gene is the major genetic determinant of PAI-1 expression
  - Clinical presentation
    - Individuals with 4G/5G and 4G/4G genotypes, especially those with other thrombophilic risk factors, have increased risk for venous thromboembolism (VTE)
    - 4G/5G and 4G/4G genotypes are associated with increased risk of myocardial infarction (MI)
    - Some studies have associated the 5G/5G genotype with elevated risk of ischemic stroke

Alpha-2-antiplasmin

Pathophysiology
- Secreted by the liver
- Binds to and inhibits plasmin
Deficiency
- Inherited (autosomal recessive)
- Rare incidence
Clinical presentation
- Heterozygotes – usually asymptomatic or with mild mucosal bleeding
- Homozygotes – may have severe bleeding episodes resembling those of congenital hemophilia
  - Umbilical cord bleeding
  - Hemarthrosis
  - Excessive postoperative and posttrauma bleeding
Thrombotic risk
- Elevated alpha-2-antiplasmin not reported to be associated with increased thrombosis risk

ARUP Lab Tests

Tests generally appear in the order most useful for common clinical situations. Click on number for test-specific information in the ARUP Laboratory Test Directory.

Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping 2004980
Method: Polymerase Chain Reaction/Fluorescence Monitoring

Recommended Use

Screen for genetic susceptibility for VTE or MI in individuals with a personal or family history of thrombotic events

Aid risk/benefit assessment for preventive or therapeutic interventions for VTE or MI

Limitations

Variants other than the 4G/5G polymorphism are not evaluated

Diagnostic errors can occur due to rare sequence variations

Plasminogen Activator Inhibitor 1, Activity 0098781
Method: Bioimmunoassay

Recommended Use

Detect elevated concentrations of PAI-1

Low concentrations of PAI-1 may not be accurately quantified

Not a first-line test for diagnosing inherited thrombotic or bleeding disorders

Plasminogen Activity 0030190
Method: Chromogenic Assay

Recommended Use

Screen for plasminogen deficiency

Not a first-line test for diagnosing inherited thrombotic or bleeding disorders

Alpha-2-Antiplasmin, Activity 0098727
Method: Chromogenic Assay

Recommended Use

Screen for alpha-2-antiplasmin deficiency

Not a first-line test for diagnosing inherited thrombotic or bleeding disorders

Tissue Plasminogen Activator, Antigen 0099187
Method: Enzyme-Linked Immunosorbent Assay

Recommended Use

Determine quantity of tissue plasminogen in plasma

May be helpful in detecting disorders of the fibrinolytic system

Not a first-line test for diagnosing inherited thrombotic or bleeding disorders

Medical Experts

Lyon, Elaine, PhD, FACMG, Medical Director, Molecular Genetics and Genomics, Medical Director, Pharmacogenomics at ARUP Laboratories; Professor of Clinical Pathology, University of Utah

Rodgers III, George M., MD, PhD, Medical Director, Hemostasis/Thrombosis at ARUP Laboratories; Professor of Internal Medicine and Adjunct Professor of Clinical Pathology, University of Utah

Smock, Kristi J., MD, Medical Director, Hemostasis/Thrombosis at ARUP Laboratories; Associate Professor of Clinical Pathology, University of Utah

References

General References

Carpenter SL, Mathew P. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia. 2008; 14(6): 1250-4. PubMed

Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 2008; 14(6): 1255-60. PubMed

Mehta R, Shapiro AD. Plasminogen deficiency. Haemophilia. 2008; 14(6): 1261-8. PubMed

Rare Coagulation Disorders Resource Room - Rare Coagulation Disorders. Rare Coagulation Disorders Subcommittee of the National Hemophilia Foundation, and Indiana Hemophilia & Thrombosis Center. [Accessed: Apr 2018]

Schuster V, Hügle B, Tefs K. Plasminogen deficiency. J Thromb Haemost. 2007; 5(12): 2315-22. PubMed

Westrick RJ, Eitzman DT. Plasminogen activator inhibitor-1 in vascular thrombosis. Curr Drug Targets. 2007; 8(9): 966-1002. PubMed

Last Update: July 2018

Fibrinolytic Disorders

Diagnosis

Indications for Testing

Laboratory Testing

Differential Diagnosis

Background

Pathophysiology

Components of Fibrinolytic System

Plasminogen

tPA

PAI-1

Alpha-2-antiplasmin

ARUP Lab Tests

Medical Experts

References

General References

ARUP Laboratories

ARUP Websites

ARUP Consult


	[X] Topic Name Message * If ARUP Consult does not answer your test selection and interpretation questions, or if you’d like to suggest ways to improve content or usability, please leave a message for the ARUP clinical content team. Please do not include any patient-specific or personal health information (PHI) in your message. Email Address An email address is not required, but providing one allows the ARUP Consult clinical content team to respond directly. ARUP will only use your email address to respond to your feedback. See the ARUP privacy policy for more information regarding email use. Leave this field blank


	Fibrinolytic Disorders. ARUP Consult^©. Retrieved February 15, 2019, from: https://arupconsult.com/content/fibrinolytic-disorders